Efficacy and Safety of Long-term Oral Staphylococcus Albicans Tablets in Patients With Bronchiectasis

Qianfoshan Hospital

Status

Enrolling

Conditions

Bronchiectasis

Treatments

Other: On-demand treatment

Drug: Staphylococcus and Neisseria Tablets

Study type

Interventional

Funder types

Other

Identifiers

NCT05407792

2022-5-26-QFS

Details and patient eligibility

About

The main purpose of this study is to investigate whether long-term oral administration of Staphylococcus albicans tablets can significantly reduce the number of acute exacerbations in patients with bronchiectasis. Secondary objective is to explore whether long-term oral administration of Staphylococcus albicans tablets can reduce the risk of hospitalization in patients with bronchiectasis and whether it can improve the quality of life of patients. Other purpose is to explore the regulatory effect of long-term oral administration of Staphylococcus albicans tablets on the immune function of patients with bronchiectasis.

Full description

Bronchiectasis is a chronic airway purulent disease. The four factors of "vicious circle" play an important role in the occurrence, development and prognosis of bronchiectasis. Attempts to breaks the vicious circle may be beneficial to reduce the acute exacerbation of bronchiectasis. The main ingredients of Staphylococcus albicans tablets are the inactivated cells of Staphylococcus albus, Catarella catarrhalis and Bacillus subtilis. It may be beneficial to improve the non-specific immunity of patients and the specific immune function of respiratory mucosa, and reduce airway mucus secretion and secretion retention. There is not yet sufficient clinical evidence to support the immune function regulation and related efficacy of patients. Therefore, the efficacy of long-term oral administration of Staphylococcus albicans tablets in patients with bronchiectasis needs to be further confirmed by clinical studies.

Enrollment

134 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients with bronchiectasis diagnosed by clinical manifestations and chest HRCT according to the diagnostic criteria for bronchiectasis;
- Patients with idiopathic or post-infectious bronchiectasis;
  - 18years old;
    - Patients should have at least 2 acute exacerbations within 1 year before enrollment;
      - Patients in either acute exacerbation or stable period can be included.

Exclusion criteria

Cystic fibrosis;
- Immunodeficiency, allergic bronchopulmonary aspergillosis, etc.;
  - Traction bronchiectasis caused by severe emphysema or advanced pulmonary fibrosis;
    - Still smoking;
      - Complicated with asthma or chronic obstructive disease Lung;
        
        Patients with severe cardiovascular disease, severe neurological disease, or severe liver or kidney damage;
        
        Malignant tumors;
        
        Allergy to Staphylococcus albicans tablets;
        
        Patients with a history of gastric ulcer or intestinal malabsorption;
        
        Pregnant or lactating women;
        
        patients with poor compliance;
        
        previous (within 6 months before the start of the study) or concurrently taking immunostimulating drugs (including thymosin, interferon, transfer factor, BCG, pneumonia vaccine and any kind of bacteria Extracts, such as Biostim, except for influenza vaccine) or immunosuppressants;
        
        Patients who are participating in or have participated in interventional clinical trials within 3 months.